Impax now to co-promote Pfizer's Lyrica; updates on APEX-PD trial; Pfizer in deal with Stemgent on reagents
Impax Pharmaceuticals, the brand products division of Impax Laboratories, has amended its 2008 co-promotion agreement with Wyeth, now a wholly owned subsidiary of global drugs behemoth Pfizer. Effective April 1, Impax has started detailing Lyrica (pregabalin) CV for use as adjunctive therapy for adult patients with partial onset seizures to neurologists.
However, Impax has agreed to discontinue detailing Pristiq (desvenlafaxine extended-release tablets), for the treatment of depression, which it had been co-promoting under a July 2009 deal with Wyeth. Lyrica is approved as a treatment for nerve pain, seizures, and fibromyalgia.
Impax completes APEX-PD trial
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze